@article{175ddd777b5c4f378d961d55d49ea792,
title = "Should Polypills Be Used for Heart Failure With Reduced Ejection Fraction?",
keywords = "evidence-based practice, heart failure, heart failure, systolic, practice guidelines as topic",
author = "Ambarish Pandey and Neil Keshvani and Wang, {Thomas J.}",
note = "Funding Information: Drs Pandey and Wang are supported by R01MD017529 from the National Institute of Minority and Health Disparities. Dr Pandey is also supported by the National Institute of Aging (GEMSSTAR grant R03AG067960) Funding Information: Dr Pandey has received research grant support from the Gilead Sciences Research Scholar Program and Applied Therapeutics; honoraria outside the present study as an advisor/consultant for Tricog Health Inc and Lilly, USA, Rivus, and Roche Diagnostics, and nonfinancial support from Pfizer and Merck. Dr Wang is named as a co-inventor on a pending patent application on novel biomarkers of heart failure, and he has participated in a data science advisory board for Novartis. Dr Keshvani reports no conflicts.",
year = "2022",
month = jul,
day = "26",
doi = "10.1161/CIRCULATIONAHA.122.059661",
language = "English (US)",
volume = "146",
pages = "276--278",
journal = "Circulation",
issn = "0009-7322",
publisher = "Lippincott Williams and Wilkins",
number = "4",
}